All In MedTech

Device Trial Radar · NCT05932615

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

1,500

Planned (sponsor's estimate)

Start

Mar 15, 2024

Primary completion

Apr 2027

Study completion Apr 2036

Sponsor

Lead sponsor
Abbott Medical DevicesPublic (ABT)
Sponsor type
Industry
First posted
Jul 6, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality. The trial will also evaluate the safety and effectiveness of the Navitor TAVI System in a valve-in-valve (ViV) application in patients with symptomatic heart disease due to failure of a surgical or transcatheter bioprosthetic aortic valve who are at high or greater surgical risk. In addition, the trial will assess the safety of the Navitor TAVI System for the treatment of symptomatic, severe native aortic stenosis in patients with bicuspid aortic valve anatomy, irrespective of surgical risk classification.

Conditions

  • Aortic Valve Stenosis
  • Heart Valve Diseases
  • Aortic Valve Disease
  • Heart Disease Structural Disorder

Interventions

  • Navitor Transcatheter Aortic Valve Implantation (TAVI) SystemDevice

    TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.

  • Any Commercially Available Transcatheter Aortic Valve (CAV) SystemDevice

    TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of all-cause mortality or all strokeTime frame: At 12 months post-procedure

Locations

107 sites in 13 countries. Site status is shown where the registry gives one.

  • University Hospital - Univ. of Alabama at Birmingham (UAB)

    Birmingham, Alabama

  • St. Joseph's Hospital & Medical Center

    Phoenix, Arizona

  • Tucson Medical Center

    Tucson, Arizona

104 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.